GSE141174

Genome-wide analysis of colorectal cancer gene expression by using primary tumors, normal colon and lymph nodes

Whole-study status Needs manual review

Scores are usable, but sample metadata contains review-only concerns.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

8 case / 8 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

Analysis of the difference in gene expression between colorectal cancer samples and control samples

Overall design

Total RNA was extracted from colorectal cancer primary tumors and lymph nodes metastasis and compared to RNA extracted from lymph nodes and colon tissue of control patients

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
16 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

4 linked publications 4 DOIs

Primary publication

  1. Allocating colorectal cancer patients to different risk categories by using a five-biomarker mRNA combination in lymph node analysis. PloS one, 2020

Related publications

  1. E3 Ubiquitination Ligase MYLIP Mediates the NKRF/SLC25A34 Axis to Suppress Malignant Progression in Colorectal Cancer. Digestive diseases and sciences, 2025
  2. ITLN1 suppresses colorectal cancer progression by inhibiting Wnt/β-catenin-mediated EMT and reprogramming macrophage polarization. International immunopharmacology, 2026
  3. SPINK4 modulates inhibition of glycolysis against colorectal cancer progression. Biomolecules & biomedicine, 2024
Available

Metadata Quality Components

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Needs manual review Scores are usable, but sample metadata contains review-only concerns.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease, colorectal cancer, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Colorectal cancer 8 samples
  • Likely control group Control 8 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded assay: microarray cohorts are separated from the RNA-seq intent. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Tumor vs unmatched normal. Specimen: Tissue. Comparison suitability: 100%.
  • Interpreted disease metadata: Colorectal cancer, Crohn's disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 4 publications; 4 DOIs available: PMID 32049988, PMID 38747892, PMID 39661280, PMID 41747601.
  • Publication context: Allocating colorectal cancer patients to different risk categories by using a five-biomarker mRNA combination in lymph node analysis.. PloS one, 2020. PMID 32049988. DOI 10.1371/journal.pone.0229007.
  • Publication context: SPINK4 modulates inhibition of glycolysis against colorectal cancer progression.. Biomolecules & biomedicine, 2024. PMID 38747892. DOI 10.17305/bb.2024.10338.
  • Publication context: E3 Ubiquitination Ligase MYLIP Mediates the NKRF/SLC25A34 Axis to Suppress Malignant Progression in Colorectal Cancer.. Digestive diseases and sciences, 2025. PMID 39661280. DOI 10.1007/s10620-024-08735-9.
  • Publication context: 1 additional linked PubMed publications are available.

Cautions

  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.

Dataset Warnings

Normalized Fields

46 fields

Sample Group Preview

16 rows shown
Show Hide
Study totals: Case 8 | Control 8 | Unassigned 0 | Excluded 0 | Ambiguous 0 16 rows shown
Group Role Accession Title Source / characteristics Reason
Colorectal cancer Case GSM4196531 Colorectal cancer lymph node no1 Lymph node Disease state: Stage III Case marker detected.
Colorectal cancer Case GSM4196532 Colorectal cancer lymph node no1_2 Lymph node Disease state: Stage III Case marker detected.
Colorectal cancer Case GSM4196533 Colorectal cancer lymph node no2 Lymph node Disease state: Stage III Case marker detected.
Tumor sample Case GSM4196537 Colorectal cancer primary tumor no1 Primary tumor Disease state: Stage III Explicit sample label case marker detected.
Colorectal cancer Case GSM4196539 Colorectal cancer lymph node no3 Lymph node Disease state: Stage III Case marker detected.
Colorectal cancer Case GSM4196540 Colorectal cancer lymph node no4 Lymph node Disease state: Stage III Case marker detected.
Tumor sample Case GSM4196543 Colorectal cancer primary tumor no2 Primary tumor Disease state: Stage III Explicit sample label case marker detected.
Tumor sample Case GSM4196544 Colorectal cancer primary tumor no3 Primary tumor Disease state: Stage III Explicit sample label case marker detected.
Control Control GSM4196534 Control lymph node no1 UC Lymph node Disease state: Ulcerative colitis Sample-local control marker detected.
Control Control GSM4196535 Control lymph node no2 Lymph node Disease state: Lipoma Sample-local control marker detected.
Control Control GSM4196536 Control lymph node no2_2 Lymph node Disease state: Lipoma Sample-local control marker detected.
Normal tissue Control GSM4196538 Normal colon no1 Normal colon Disease state: Normal colon Sample-local control marker detected.
Control Control GSM4196541 Control lymph node no3 Lymph node Disease state: Ulcerative colitis Sample-local control marker detected.
Control Control GSM4196542 Control lymph node no4 Lymph node Disease state: Crohn's disease Sample-local control marker detected.
Normal tissue Control GSM4196545 Normal colon no2 Normal colon Disease state: Normal colon Sample-local control marker detected.
Normal tissue Control GSM4196546 Normal colon no3 Normal colon Disease state: Normal colon Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.